Ultragenyx Pharmaceutical Inc (NAS:RARE)
$ 57.87 1.5 (2.66%) Market Cap: 5.33 Bil Enterprise Value: 4.46 Bil PE Ratio: 0 PB Ratio: 12.33 GF Score: 74/100

Q1 2022 Ultragenyx Pharmaceutical Inc Earnings Call Transcript

May 05, 2022 / 09:00PM GMT
Release Date Price: $66.43 (-6.34%)
Operator

Good day, and thank you for standing by. Welcome to the Ultragenyx First Quarter 2021 Financial Results and Corporate Update Conference Call. (Operator Instructions). Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Joshua Higa.

Joshua Higa
Ultragenyx Pharmaceutical Inc. - Director of IR & Corporate Communications

Good afternoon, and welcome to the Ultragenyx Pharmaceutical Financial Results and Corporate Update Conference Call for the First Quarter of 2022. We have issued press release detailing our financial results, which you can find on our website at ultragenyx.com.

I am Joshua Higa, Director of Investor Relations. Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Erik Harris, Chief Commercial Officer; Mardi Dier, Chief Financial Officer; and Camille Bedrosian, Chief Medical Officer.

I would like to remind everyone that during today's call, we will be making forward-looking statements. These

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot